Reversible thyroid dysfunction during treatment with GM-CSF

K. Hoekman, J. Wagstaff, H. M. Pinedo, B. M E von Blomberg-van der Flier, H. A. Drexhage

Research output: Contribution to journal › Article

Abstract

To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250 μg/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.

Original languageEnglish (US)
Pages (from-to)541-542
Number of pages2
JournalThe Lancet
Volume338
Issue number8766
DOIs
StatePublished - Aug 31 1991
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Thyroid Gland
Therapeutics
Antigen-Presenting Cells
Autoimmunity
Sarcoma
Autoantibodies
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Antigens
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hoekman, K., Wagstaff, J., Pinedo, H. M., von Blomberg-van der Flier, B. M. E., & Drexhage, H. A. (1991). Reversible thyroid dysfunction during treatment with GM-CSF. The Lancet, 338(8766), 541-542. https://doi.org/10.1016/0140-6736(91)91103-2

Reversible thyroid dysfunction during treatment with GM-CSF. / Hoekman, K.; Wagstaff, J.; Pinedo, H. M.; von Blomberg-van der Flier, B. M E; Drexhage, H. A.

In: The Lancet, Vol. 338, No. 8766, 31.08.1991, p. 541-542.

Research output: Contribution to journal › Article

Hoekman, K, Wagstaff, J, Pinedo, HM, von Blomberg-van der Flier, BME & Drexhage, HA 1991, 'Reversible thyroid dysfunction during treatment with GM-CSF', The Lancet, vol. 338, no. 8766, pp. 541-542. https://doi.org/10.1016/0140-6736(91)91103-2
Hoekman K, Wagstaff J, Pinedo HM, von Blomberg-van der Flier BME, Drexhage HA. Reversible thyroid dysfunction during treatment with GM-CSF. The Lancet. 1991 Aug 31;338(8766):541-542. https://doi.org/10.1016/0140-6736(91)91103-2
Hoekman, K. ; Wagstaff, J. ; Pinedo, H. M. ; von Blomberg-van der Flier, B. M E ; Drexhage, H. A. / Reversible thyroid dysfunction during treatment with GM-CSF. In: The Lancet. 1991 ; Vol. 338, No. 8766. pp. 541-542.
@article{21b5d3a6838b412fbe744cca2bb3d3b2,
title = "Reversible thyroid dysfunction during treatment with GM-CSF",
abstract = "To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250 μg/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.",
author = "K. Hoekman and J. Wagstaff and Pinedo, {H. M.} and {von Blomberg-van der Flier}, {B. M E} and Drexhage, {H. A.}",
year = "1991",
month = "8",
day = "31",
doi = "10.1016/0140-6736(91)91103-2",
language = "English (US)",
volume = "338",
pages = "541--542",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8766",

}

TY - JOUR

T1 - Reversible thyroid dysfunction during treatment with GM-CSF

AU - Hoekman, K.

AU - Wagstaff, J.

AU - Pinedo, H. M.

AU - von Blomberg-van der Flier, B. M E

AU - Drexhage, H. A.

PY - 1991/8/31

Y1 - 1991/8/31

N2 - To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250 μg/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.

AB - To investigate whether autoimmunity against thyroid antigens is induced or exacerbated by granulocyte-macrophage colony-stimulating factor, thyroid function and thyroid autoantibodies were studied in 14 patients with advanced breast cancer and 11 with soft-tissue sarcoma who received several cycles of doxorubicin and cyclophosphamide plus GM-CSF 250 μg/m2 intravenously daily for 10 days in every 21 day cycle. All patients had normal thyroid function before treatment. In 2 patients with pre-existing thyroid antibodies, thyroid dysfunction developed but disappeared after cessation of GM-CSF. No other autoimmune abnormalities appeared. Stimulation of antigen-presenting cells by GM-CSF may bring about this phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=0025916048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025916048&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)91103-2

DO - 10.1016/0140-6736(91)91103-2

M3 - Article

VL - 338

SP - 541

EP - 542

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8766

ER -

Access to Document